The effects of repeated nocturnal doses of clobazam, dipotassium chlorazepate and placebo on subjective ratings of sleep and early morning behaviour and objective measures of arousal, psychomotor performance and anxiety.
1. Repeated nocturnal doses of 30 mg clobazam and dipotassium chlorazepate 15 mg showed no significant effects compared to matching placebo on tests of psychomotor performance and serial subtraction of numbers given in the morning and afternoon of the day following treatment. 2. Both active preparations improved the perceived quality of sleep compared to placebo. 3. A reduction in rated anxiety scores was found with clobazam on the afternoon of the day following treatment together with an elevation of critical flicker fusion thresholds. 4. Dipotassium chlorazepate was found to impair performance of a low level conceptual task but not to influence performance at a more difficult level.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D001143:Arousal / Q000187:drug effects; D001519:Behavior / Q000187:drug effects*; D001570:Benzodiazepinones / Q000494:pharmacology* / Q000627:therapeutic use; D003009:Clorazepate Dipotassium / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009048:Motor Skills / Q000187:drug effects*; D010919:Placebos; D012890:Sleep / Q000187:drug effects*
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D010919:Placebos; D003009:Clorazepate Dipotassium